Danielle Antin‐Ozerkis

Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

Athol U. Wells, Kevin R. Flaherty, Kevin K. Brown et al. · The Lancet Respiratory Medicine · 2020 · 559 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +12

Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype

Susan Mathai, Mridu Gulati, Xueyan Peng et al. · Laboratory Investigation · 2010 · 235 citations · Full text

Medicine, Immunology, Pathology +12

Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis

Ganesh Raghu, Bernt van den Blink, Mark J. Hamblin et al. · JAMA · 2018 · 225 citations · Full text

Health Professions, Pharmacology, Pharmacotherapy +17

Extracellular Mitochondrial DNA Is Generated by Fibroblasts and Predicts Death in Idiopathic Pulmonary Fibrosis

Changwan Ryu, Huanxing Sun, Mridu Gulati et al. · American Journal of Respiratory and Critical Care Medicine · 2017 · 172 citations

Life Sciences, Cell Biology, Pathology +17

2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases

Sindhu R. Johnson, Elana J. Bernstein, Marcy B. Bolster et al. · Arthritis & Rheumatology · 2024 · 166 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +16